With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...

The American College of Cardiology has issued new guidelines recommending weight management medications as first-line ...

While the makers of Ozempic have stated that their GLP-1 medication was not made to be used as a weight loss drug, nor should ...

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...

Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average.

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

New research suggests bariatric surgery delivers significantly greater weight loss compared to popular GLP-1 drugs. The study ...

Both products contain semaglutide as the active ingredient ... Mounjaro / Zepbound are brands for tirzepatide, targeting ...

Researchers found after bariatric procedures, patients lost an average of 58 pounds after two years, compared to 12 pounds ...